Diametric Capital LP Sells 35,423 Shares of Indivior PLC (NASDAQ:INDV)

Diametric Capital LP trimmed its stake in shares of Indivior PLC (NASDAQ:INDV) by 53.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 30,487 shares of the company’s stock after selling 35,423 shares during the quarter. Diametric Capital LP’s holdings in Indivior were worth $391,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Indivior during the fourth quarter worth $56,000. Stifel Financial Corp acquired a new stake in shares of Indivior during the 3rd quarter valued at $100,000. Melqart Asset Management UK Ltd bought a new stake in Indivior during the 3rd quarter worth $132,000. Jane Street Group LLC acquired a new position in Indivior in the 3rd quarter worth about $180,000. Finally, Public Employees Retirement System of Ohio bought a new position in Indivior in the third quarter valued at about $294,000. Institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

Shares of INDV opened at $9.38 on Wednesday. The business has a 50-day moving average of $10.14 and a 200-day moving average of $10.38. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -26.80 and a beta of 0.82. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $22.53.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The business had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. As a group, sell-side analysts anticipate that Indivior PLC will post 1.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Piper Sandler dropped their price target on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.